Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

Louise de Swart, Alex Smith, Detlef Haase, Pierre Fenaux, Argiris Symeonidis, Jaroslav Cermak, Guillermo Sanz, Reinhard Stauder, Moshe Mittelman, Eva Hellström-Lindberg, Luca Malcovati, Saskia Langemeijer, Mette Skov-Holm, Krzysztof Mądry, Ulrich Germing, Antonio Medina Almeida, Aurelia Tatic, Aleksandar Savic, Njetočka Gredelj Šimec, Corine van MarrewijkAgnes Guerci-Bresler, Laurence Sanhes, Elisa Luño, Dominic Culligan, Odile Beyne-Rauzy, Sonja Burgstaller, Nicole Blijlevens, David Bowen, Theo de Witte

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Conventional karyotype is one of the most relevant prognostic factors in MDS. However, about 50% of patients with MDS have a normal karyotype. Usually, 20–25 normal metaphases (nMP) are considered to be optimal to exclude small abnormal clones which might be associated with poor prognosis. This study evaluated the impact of examining a suboptimal number of metaphases in patients recruited to the EUMDS Registry with low and intermediate-1 risk according to IPSS. Only 179/1049 (17%) of patients with a normal karyotype had a suboptimal number of nMP, defined as less than 20 metaphases analyzed. The outcome (overall survival and progression-free survival) of patients with suboptimal nMP was not inferior to those with higher numbers of analyzed MP both in univariate and multivariate analyses. For patients with an abnormal karyotype, 224/649 (35%) had a suboptimal number of MP assessed, but this did not impact on outcome. For patients with a normal karyotype and suboptimal numbers of analyzable metaphases standard evaluation might be acceptable for general practice, but we recommend additional FISH-analyses or molecular techniques, especially in candidates for intensive interventions.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalLeukemia Research
Volume67
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Metaphase
Karyotype
Abnormal Karyotype
General Practice
Disease-Free Survival
Registries
Multivariate Analysis
Clone Cells
Survival

Keywords

  • Cytogenetics
  • Karyotype
  • Lower-risk
  • Metaphases
  • Myelodysplastic syndromes
  • Overall survival
  • Progression-free survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

de Swart, L., Smith, A., Haase, D., Fenaux, P., Symeonidis, A., Cermak, J., ... de Witte, T. (2018). Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. Leukemia Research, 67, 21-26. https://doi.org/10.1016/j.leukres.2018.01.022

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. / de Swart, Louise; Smith, Alex; Haase, Detlef; Fenaux, Pierre; Symeonidis, Argiris; Cermak, Jaroslav; Sanz, Guillermo; Stauder, Reinhard; Mittelman, Moshe; Hellström-Lindberg, Eva; Malcovati, Luca; Langemeijer, Saskia; Skov-Holm, Mette; Mądry, Krzysztof; Germing, Ulrich; Almeida, Antonio Medina; Tatic, Aurelia; Savic, Aleksandar; Šimec, Njetočka Gredelj; van Marrewijk, Corine; Guerci-Bresler, Agnes; Sanhes, Laurence; Luño, Elisa; Culligan, Dominic; Beyne-Rauzy, Odile; Burgstaller, Sonja; Blijlevens, Nicole; Bowen, David; de Witte, Theo.

In: Leukemia Research, Vol. 67, 01.04.2018, p. 21-26.

Research output: Contribution to journalArticle

de Swart, L, Smith, A, Haase, D, Fenaux, P, Symeonidis, A, Cermak, J, Sanz, G, Stauder, R, Mittelman, M, Hellström-Lindberg, E, Malcovati, L, Langemeijer, S, Skov-Holm, M, Mądry, K, Germing, U, Almeida, AM, Tatic, A, Savic, A, Šimec, NG, van Marrewijk, C, Guerci-Bresler, A, Sanhes, L, Luño, E, Culligan, D, Beyne-Rauzy, O, Burgstaller, S, Blijlevens, N, Bowen, D & de Witte, T 2018, 'Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS', Leukemia Research, vol. 67, pp. 21-26. https://doi.org/10.1016/j.leukres.2018.01.022
de Swart, Louise ; Smith, Alex ; Haase, Detlef ; Fenaux, Pierre ; Symeonidis, Argiris ; Cermak, Jaroslav ; Sanz, Guillermo ; Stauder, Reinhard ; Mittelman, Moshe ; Hellström-Lindberg, Eva ; Malcovati, Luca ; Langemeijer, Saskia ; Skov-Holm, Mette ; Mądry, Krzysztof ; Germing, Ulrich ; Almeida, Antonio Medina ; Tatic, Aurelia ; Savic, Aleksandar ; Šimec, Njetočka Gredelj ; van Marrewijk, Corine ; Guerci-Bresler, Agnes ; Sanhes, Laurence ; Luño, Elisa ; Culligan, Dominic ; Beyne-Rauzy, Odile ; Burgstaller, Sonja ; Blijlevens, Nicole ; Bowen, David ; de Witte, Theo. / Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. In: Leukemia Research. 2018 ; Vol. 67. pp. 21-26.
@article{a311c5e1984b45a2b9d9e489cec33584,
title = "Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS",
abstract = "Conventional karyotype is one of the most relevant prognostic factors in MDS. However, about 50{\%} of patients with MDS have a normal karyotype. Usually, 20–25 normal metaphases (nMP) are considered to be optimal to exclude small abnormal clones which might be associated with poor prognosis. This study evaluated the impact of examining a suboptimal number of metaphases in patients recruited to the EUMDS Registry with low and intermediate-1 risk according to IPSS. Only 179/1049 (17{\%}) of patients with a normal karyotype had a suboptimal number of nMP, defined as less than 20 metaphases analyzed. The outcome (overall survival and progression-free survival) of patients with suboptimal nMP was not inferior to those with higher numbers of analyzed MP both in univariate and multivariate analyses. For patients with an abnormal karyotype, 224/649 (35{\%}) had a suboptimal number of MP assessed, but this did not impact on outcome. For patients with a normal karyotype and suboptimal numbers of analyzable metaphases standard evaluation might be acceptable for general practice, but we recommend additional FISH-analyses or molecular techniques, especially in candidates for intensive interventions.",
keywords = "Cytogenetics, Karyotype, Lower-risk, Metaphases, Myelodysplastic syndromes, Overall survival, Progression-free survival",
author = "{de Swart}, Louise and Alex Smith and Detlef Haase and Pierre Fenaux and Argiris Symeonidis and Jaroslav Cermak and Guillermo Sanz and Reinhard Stauder and Moshe Mittelman and Eva Hellstr{\"o}m-Lindberg and Luca Malcovati and Saskia Langemeijer and Mette Skov-Holm and Krzysztof Mądry and Ulrich Germing and Almeida, {Antonio Medina} and Aurelia Tatic and Aleksandar Savic and Šimec, {Njetočka Gredelj} and {van Marrewijk}, Corine and Agnes Guerci-Bresler and Laurence Sanhes and Elisa Lu{\~n}o and Dominic Culligan and Odile Beyne-Rauzy and Sonja Burgstaller and Nicole Blijlevens and David Bowen and {de Witte}, Theo",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.leukres.2018.01.022",
language = "English",
volume = "67",
pages = "21--26",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

AU - de Swart, Louise

AU - Smith, Alex

AU - Haase, Detlef

AU - Fenaux, Pierre

AU - Symeonidis, Argiris

AU - Cermak, Jaroslav

AU - Sanz, Guillermo

AU - Stauder, Reinhard

AU - Mittelman, Moshe

AU - Hellström-Lindberg, Eva

AU - Malcovati, Luca

AU - Langemeijer, Saskia

AU - Skov-Holm, Mette

AU - Mądry, Krzysztof

AU - Germing, Ulrich

AU - Almeida, Antonio Medina

AU - Tatic, Aurelia

AU - Savic, Aleksandar

AU - Šimec, Njetočka Gredelj

AU - van Marrewijk, Corine

AU - Guerci-Bresler, Agnes

AU - Sanhes, Laurence

AU - Luño, Elisa

AU - Culligan, Dominic

AU - Beyne-Rauzy, Odile

AU - Burgstaller, Sonja

AU - Blijlevens, Nicole

AU - Bowen, David

AU - de Witte, Theo

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Conventional karyotype is one of the most relevant prognostic factors in MDS. However, about 50% of patients with MDS have a normal karyotype. Usually, 20–25 normal metaphases (nMP) are considered to be optimal to exclude small abnormal clones which might be associated with poor prognosis. This study evaluated the impact of examining a suboptimal number of metaphases in patients recruited to the EUMDS Registry with low and intermediate-1 risk according to IPSS. Only 179/1049 (17%) of patients with a normal karyotype had a suboptimal number of nMP, defined as less than 20 metaphases analyzed. The outcome (overall survival and progression-free survival) of patients with suboptimal nMP was not inferior to those with higher numbers of analyzed MP both in univariate and multivariate analyses. For patients with an abnormal karyotype, 224/649 (35%) had a suboptimal number of MP assessed, but this did not impact on outcome. For patients with a normal karyotype and suboptimal numbers of analyzable metaphases standard evaluation might be acceptable for general practice, but we recommend additional FISH-analyses or molecular techniques, especially in candidates for intensive interventions.

AB - Conventional karyotype is one of the most relevant prognostic factors in MDS. However, about 50% of patients with MDS have a normal karyotype. Usually, 20–25 normal metaphases (nMP) are considered to be optimal to exclude small abnormal clones which might be associated with poor prognosis. This study evaluated the impact of examining a suboptimal number of metaphases in patients recruited to the EUMDS Registry with low and intermediate-1 risk according to IPSS. Only 179/1049 (17%) of patients with a normal karyotype had a suboptimal number of nMP, defined as less than 20 metaphases analyzed. The outcome (overall survival and progression-free survival) of patients with suboptimal nMP was not inferior to those with higher numbers of analyzed MP both in univariate and multivariate analyses. For patients with an abnormal karyotype, 224/649 (35%) had a suboptimal number of MP assessed, but this did not impact on outcome. For patients with a normal karyotype and suboptimal numbers of analyzable metaphases standard evaluation might be acceptable for general practice, but we recommend additional FISH-analyses or molecular techniques, especially in candidates for intensive interventions.

KW - Cytogenetics

KW - Karyotype

KW - Lower-risk

KW - Metaphases

KW - Myelodysplastic syndromes

KW - Overall survival

KW - Progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=85041672268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041672268&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2018.01.022

DO - 10.1016/j.leukres.2018.01.022

M3 - Article

AN - SCOPUS:85041672268

VL - 67

SP - 21

EP - 26

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -